DOCSLIB.ORG

Fetal Sex and RHD Genotyping with Digital PCR Demonstrates Greater Sensitivity Than Real-Time PCR

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fetal Sex and RHD Genotyping with Digital PCR Demonstrates Greater Sensitivity Than Real-Time PCR University of Plymouth PEARL https://pearl.plymouth.ac.uk Faculty of Health: Medicine, Dentistry and Human Sciences School of Biomedical Sciences 2015-11 Fetal Sex and RHD Genotyping with Digital PCR Demonstrates Greater Sensitivity than Real-time PCR. Sillence, KA http://hdl.handle.net/10026.1/3798 10.1373/clinchem.2015.239137 Clin Chem All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author. Clinical Chemistry 61:11 Molecular Diagnostics and Genetics 1399–1407 (2015) Fetal Sex and RHD Genotyping with Digital PCR Demonstrates Greater Sensitivity than Real-time PCR Kelly A. Sillence,1 Llinos A. Roberts,2 Heidi J. Hollands,2 Hannah P. Thompson,1 Michele Kiernan,1 Tracey E. Madgett,1 C. Ross Welch,2 and Neil D. Avent1* BACKGROUND: Noninvasive genotyping of fetal RHD inconclusive results, particularly when samples express (Rh blood group, D antigen) can prevent the unnecessary high levels of background maternal cell-free DNA. administration of prophylactic anti-D to women carry- © 2015 American Association for Clinical Chemistry ing RHD-negative fetuses. We evaluated laboratory methods for such genotyping. Diagnosis of fetal sex, RHD (Rh blood group, D anti- METHODS: Blood samples were collected in EDTA tubes gen)3 genotype, and chromosomal abnormalities can be and Streck® Cell-Free DNA™ blood collection tubes achieved only through analysis of fetal DNA. Initially, (Streck BCTs) from RHD-negative women (n ϭ 46). this could be achieved through invasive procedures such Using Y-specific and RHD-specific targets, we investi- as amniocentesis and chorionic villus sampling, quoted as gated variation in the cell-free fetal DNA (cffDNA) frac- having a 1% risk of miscarriage (1). Since the discovery tion and determined the sensitivity achieved for optimal 4 and suboptimal samples with a novel Droplet Digital™ of cell-free fetal DNA (cffDNA) in maternal plasma, PCR (ddPCR) platform compared with real-time quan- noninvasive prenatal testing is now a clinical reality (1– titative PCR (qPCR). 5). Fetal sex determination is offered in the clinic for families at risk of X-linked disorders, such as Duchenne RESULTS: The cffDNA fraction was significantly larger for muscular dystrophy (6). Determination of fetal sex is samples collected in Streck BCTs compared with samples especially beneficial in cases of congenital adrenal hyper- collected in EDTA tubes (P Ͻ 0.001). In samples expressing plasia, to allow therapy to be targeted to female fetuses optimal cffDNA fractions (Ն4%), both qPCR and digital only (7). Fetal aneuploidy detection requires accurate PCR (dPCR) showed 100% sensitivity for the TSPY1 quantification and presently can only be determined by (testis-specific protein, Y-linked 1) and RHD7 (RHD exon next-generation sequencing, which is too costly for rou- 7) assays. Although dPCR also had 100% sensitivity for tine testing (8). RHD5 (RHD exon 5), qPCR had reduced sensitivity (83%) The antigens of the Rh blood group system are for this target. For samples expressing suboptimal cffDNA coded for by 2 genes, RHD and RHCE (Rh blood group, fractions (Ͻ2%), dPCR achieved 100% sensitivity for all CcEe antigens), which are located on chromosome 1 assays, whereas qPCR achieved 100% sensitivity only for (p34–p36) (9). In white populations, most D-negative the TSPY1 (multicopy target) assay. phenotypes result from a complete RHD deletion (10). For D-negative individuals of African descent, only 18% CONCLUSIONS: qPCR was not found to be an effective are a result of RHD deletion. Instead, 66% and 15% of tool for RHD genotyping in suboptimal samples (Ͻ2% D-negative Africans have an inactive RHD gene cffDNA). However, when testing the same suboptimal (RHD⌿) or a hybrid gene (RHD-CE-DS or r’S), which do samples on the same day by dPCR, 100% sensitivity was not produce any RhD protein (10, 11). Many laborato- achieved for both fetal sex determination and RHD geno- ries currently provide noninvasive fetal RHD genotyping typing. Use of dPCR for identification of fetal specific for alloimmunized women as routine practice to manage markers can reduce the occurrence of false-negative and hemolytic disease of the fetus and newborn (HDFN) 1 School of Biomedical and Healthcare Sciences, Plymouth University, Plymouth Univer- naute RISC catalytic component 1 (formerly EIF2C1); TERT, telomerase reverse transcrip- sity Peninsula Schools of Medicine and Dentistry, Plymouth, UK; 2 Department of Fetal tase; ERV3–1, endogenous retrovirus group 3, member 1. Medicine, Plymouth Hospitals National Health Service Trust, Plymouth, UK. 4 Nonstandard abbreviations: cffDNA, cell-free fetal DNA; HDFN, hemolytic disease of the * Address correspondence to this author at: School of Biomedical and Healthcare Sciences, fetus and newborn; qPCR, real-time quantitative PCR; dPCR, digital PCR; BCT, blood Plymouth University, Plymouth, UK PL4 8AA. E-mail [email protected]. collection tube; cfDNA, cell-free DNA; RHD5, Rh blood group, D antigen exon 5; RHD7, Received January 28, 2015; accepted August 24, 2015. Rh blood group, D antigen exon 7; FAM, carboxyfluorescein; HEX, hexachlorofluores- Previously published online at DOI: 10.1373/clinchem.2015.239137 cein; BLAST, Basic Local Alignment Search Tool; gDNA, genomic DNA; ddPCR, droplet © 2015 American Association for Clinical Chemistry digital PCR; Cq, quantification cycle; Ta, annealing temperature; NTC, no-template con- 3 Human genes: RHD, Rh blood group, D antigen; RHCE, Rh blood group, CcEe antigens; trol; 2D, 2-dimensional. SRY, sex-determining region Y; TSPY1, testis-specific protein, Y-linked 1; AGO1, argo- 1399 Table 1. Summary of amplicon location, length, and fluorescent label for each multiplex reaction. Multiplex Fluorescent reaction Amplicon Chromosome Gene Exon/intron reporter dye Length, bp Origin 1 Target Y SRY Exon FAM 137 Lo et al. (22) 2 Target Y TSPY1 Exon FAM 88 In-house 1 and 2 Reference X Xp22.3 Intron HEX 95 Fan et al. (23) 3 Target 1 RHD5 Exon (5) FAM 82 Finning et al. (24) 4 Target 1 RHD7 Exon (7) FAM 75 Finning et al. (24) 3 and 4 Reference 1 AGO1 Exon HEX 81 Fan et al. (23) (4, 12–14). Before 1970, HDFN was a major cause of SAMPLE PROCESSING fetal mortality (46/100 000 births in the UK alone) (15), Twenty-two maternal peripheral blood samples were col- but since the introduction of routine antenatal anti-D pro- lected in EDTA tubes (5–10 mL total blood volume) and phylaxis, incidence has decreased nearly 10-fold (16). Cur- centrifuged at 1600g for 10 min at room temperature rently, all RHD-negative women in the West are offered this (samples 1–22). The plasma was carefully removed and prophylaxis, which is costly, as it is produced from hyper- transferred to a 15-mL tube. The plasma was then recen- immunized male volunteers. Providing a noninvasive test trifuged at 16 000g for 10 min. All samples were pro- for fetal RHD genotyping allows administration to be tar- cessed within4hofcollection, and plasma aliquots (1 ϩ Ϫ geted to RHD-negative women who are known to be carry- mL) were stored at Ϫ80 °C. RHD and RHD human ing an RHD-positive fetus. This is now routine in the Neth- whole blood, collected in EDTA tubes (5 mL total blood erlands and Denmark with real-time quantitative PCR volume), was supplied by National Health Service Blood (qPCR) approaches (4, 17, 18). However, recent publica- and Transplant (Bristol, UK) as positive and negative tions have described the application of digital PCR (dPCR) controls, respectively. These samples were processed for the detection of low-level targets with improved preci- within 48–96 h by following the same double-spin pro- sion, resulting in reliable quantification well below the limit tocol described above. of quantification of qPCR (19, 20). Twenty-four maternal blood samples collected in The use of Streck® Cell-Free DNA™ blood collec- Streck BCTs (10–20 mL total blood volume) were cen- tion tubes (BCTs) instead of conventional EDTA tubes trifuged at 1600g for 15 min at room temperature (sam- has been shown to increase the proportion of cffDNA ples 23–46). Plasma was carefully removed, transferred (21). Streck BCTs contain proprietary cell-preserving re- to a 50-mL tube, and recentrifuged at 2500g for 10 min. agents, which prevent maternal cell lysis and conse- All samples were processed within 48 h of collection, and quently reduce the amount of maternal cell-free DNA plasma aliquots (1 mL) were stored at Ϫ80 °C. (cfDNA) released into the plasma. In this study, we com- pared the sensitivity of dPCR and qPCR for the nonin- DNA EXTRACTION vasive determination of fetal sex and RHD genotype for DNA was extracted from two 1-mL aliquots of plasma samples collected in both Streck BCTs and EDTA tubes. with the QIAamp Circulating Nucleic Acid kit (Qiagen) For technical reasons, some samples, despite being col- and QIAvac 24 Plus (Qiagen). The extraction process lected in the third trimester, expressed suboptimal followed the manufacturer’s protocol, and each sample cffDNA fractions (Ͻ2%). However, all samples were in- was eluted in 60 ␮L Buffer AVE [RNase-free water con- cluded to thoroughly test the capability of the dPCR taining 0.04% (wt/vol) sodium azide]. No DNase or assay against the current gold standard, qPCR. RNase treatment was used. After DNA extraction, we quantified samples on the Qubit® 2.0 Fluorometer (Life Materials and Methods Technologies) with the Qubit dsDNA HS assay kit (Life Technologies). Samples were stored at Ϫ20 °C as 60-␮L STUDY PARTICIPANTS aliquots for Յ4 weeks.
Load more

Recommended publications
  • The Accuracy of Cell-Free Fetal DNA Based
    University of Birmingham The accuracy of cell-free fetal DNA based non- invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis Mackie, Fiona; Hemming, Karla; Allen, Stephanie; Morris, R. Katie; Kilby, Mark; MacKie, Fiona DOI: 10.1111/1471-0528.14050 License: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) Document Version Peer reviewed version Citation for published version (Harvard): Mackie, F, Hemming, K, Allen, S, Morris, RK, Kilby, M & MacKie, F 2016, 'The accuracy of cell-free fetal DNA based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis', BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.14050 Link to publication on Research at Birmingham portal Publisher Rights Statement: Checked for eligibility: 27/04/2016. This is the peer reviewed version of the following article: Mackie FL, Hemming K, Allen S, Morris RK, Kilby MD. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. BJOG 2016; DOI: 10.1111/1471-0528.14050. , which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/1471-0528.14050/full. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving." General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.
    [Show full text]
  • Applications of Cell-Free Fetal DNA in Maternal Serum Applications of Cell-Free Fetal DNA in Maternal Serum
    IJIFM 10.5005/jp-journals-10016-1038 REVIEW ARTICLE Applications of Cell-Free Fetal DNA in Maternal Serum Applications of Cell-Free Fetal DNA in Maternal Serum Saeid Ghorbian ABSTRACT approaches, such as microfluidics digital polymerase chain Cell-free fetal DNA (cffDNA) is available in the maternal reaction (PCR), reveals a higher than expected circulation throughout pregnancy and can be used for non- concentrations of fetal DNA around 10 to 12% of total DNA invasive prenatal diagnosis including, determination of fetal sex, in maternal plasma.9 The size of circulating cffDNA identification of specific single gene disorders, typing of fetal blood groups (RhD), paternity determination and potentially predominantly of short DNA fragments, 193 base pairs in routine use for Down’s syndrome (DS) testing of all pregnancies. length10 and can be detected from the 4 weeks of gestation,11 I searched published literature on the PubMed and databases though only reliably from 7 weeks, and the concentration on Scopus interface systematically using keyword’s cffDNA, noninvasive diagnosis, fetal DNA in the maternal serum. increases with gestational age with a sharp peak during the 8,12 Reference lists from the papers were also searched. cffDNA last 8 weeks of pregnancy. The half-life of cffDNA is representing only 3% of the total cell-free circulating DNA in 16 minutes and is undetectable 2 hours after delivery, early and rising to 12% in late pregnancy, clinical investigations therefore, rapidly cleared from the maternal circulation.13 has already demonstrated the potential advantage, such as 14 improving safety, earlier diagnosis and comparative ease of cffDNA may be detectable for several days.
    [Show full text]
  • Bayesian-Based Noninvasive Prenatal Diagnosis of Single-Gene Disorders
    Downloaded from genome.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press Method Bayesian-based noninvasive prenatal diagnosis of single-gene disorders Tom Rabinowitz,1 Avital Polsky,1 David Golan,2 Artem Danilevsky,1 Guy Shapira,1 Chen Raff,1 Lina Basel-Salmon,1,3 Reut Tomashov Matar,3 and Noam Shomron1 1Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 6997801, Israel; 2Faculty of Industrial Engineering and Management, Technion, Haifa, 3200003, Israel; 3Raphael Recanati Genetic Institute, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941494, Israel In the last decade, noninvasive prenatal diagnosis (NIPD) has emerged as an effective procedure for early detection of in- herited diseases during pregnancy. This technique is based on using cell-free DNA (cfDNA) and fetal cfDNA (cffDNA) in maternal blood, and hence, has minimal risk for the mother and fetus compared with invasive techniques. NIPD is currently used for identifying chromosomal abnormalities (in some instances) and for single-gene disorders (SGDs) of paternal origin. However, for SGDs of maternal origin, sensitivity poses a challenge that limits the testing to one genetic disorder at a time. Here, we present a Bayesian method for the NIPD of monogenic diseases that is independent of the mode of inheritance and parental origin. Furthermore, we show that accounting for differences in the length distribution of fetal- and maternal-de- rived cfDNA fragments results in increased accuracy. Our model is the first to predict inherited insertions–deletions (indels). The method described can serve as a general framework for the NIPD of SGDs; this will facilitate easy integration of further improvements.
    [Show full text]
  • Cffdna) Enrichment for Non-Invasive Prenatal Testing (NIPT
    Cell-free fetal DNA (cffDNA) enrichment for non-invasive prenatal testing (NIPT): a comparison of molecular techniques by Kelly A Sillence A thesis submitted to the University of Plymouth in partial fulfilment for the degree of DOCTOR OF PHILOSOPHY (December 2015) School of Biomedical and Healthcare Sciences I Copyright Statement This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without the author's prior consent. II Cell-free fetal DNA (cffDNA) enrichment for non-invasive prenatal testing (NIPT): a comparison of molecular techniques Kelly Sillence ABSTRACT Prenatal assessment of fetal health is routinely offered throughout pregnancy to ensure that the most effective management can be provided to maintain fetal and maternal well-being. Currently, invasive testing is used for definitive diagnosis of fetal aneuploidy, which is associated with a 1% risk of iatrogenic fetal loss. Developing non-invasive prenatal testing (NIPT) is a key area of research and methods to increase the level of cell-free fetal DNA (cffDNA) within the maternal circulation have been discussed to improve accuracy of such tests. In this study, three strategies; co-amplification at lower denaturation temperature polymerase chain reaction (COLD-PCR), inverse-PCR and Pippin Prep™ gel electrophoresis, were analysed to identify a novel approach to selectively enrich shorter cffDNA fragments from larger maternal cell-free DNA (cfDNA). The sensitivity of droplet digital PCR (ddPCR) against real-time PCR (qPCR) was compared for fetal sex and RHD genotyping.
    [Show full text]
  • University of Birmingham the Accuracy of Cell-Free Fetal DNA
    University of Birmingham The accuracy of cell-free fetal DNA based non- invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis Mackie, Fiona; Hemming, Karla; Allen, Stephanie; Morris, R. Katie; Kilby, Mark; MacKie, Fiona DOI: 10.1111/1471-0528.14050 License: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) Document Version Peer reviewed version Citation for published version (Harvard): Mackie, F, Hemming, K, Allen, S, Morris, RK, Kilby, M & MacKie, F 2016, 'The accuracy of cell-free fetal DNA based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis', BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.14050 Link to publication on Research at Birmingham portal Publisher Rights Statement: Checked for eligibility: 27/04/2016. This is the peer reviewed version of the following article: Mackie FL, Hemming K, Allen S, Morris RK, Kilby MD. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. BJOG 2016; DOI: 10.1111/1471-0528.14050. , which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/1471-0528.14050/full. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving." General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.
    [Show full text]
  • Noninvasive Fetal Genotyping of Paternally Inherited Alleles ISBN: 978-90-5335-545-9
    Noninvasive fetal genotyping of paternally inherited alleles ISBN: 978-90-5335-545-9 Layout: Nikki Vermeulen, Ridderprint BV, Ridderkerk, The Netherlands Print: Ridderprint BV, Ridderkerk, The Netherlands Cover illustration: Lonneke Haer-Wigman and Peter Scheffer Centrifuged sample of blood in a test tube. Photographed at Sanquin Research Amsterdam. Noninvasive fetal genotyping of paternally inherited alleles Niet-invasieve foetale genotypering van paternaal overgeërfde allelen (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op dinsdag 22 mei 2012 des ochtends te 10.30 uur door Peter Gerhard Scheffer geboren op 15 februari 1981 te Utrecht Promotores: Prof. dr. C.E. van der Schoot Prof. dr. G.H.A. Visser Co-promotores: Dr. M. de Haas Dr. G.C.M.L. Page-Christiaens Aan mijn oma† Aan mijn ouders Contents Chapter 1 General introduction and scope of the thesis 9 Chapter 2 Reliability of fetal sex determination using maternal plasma 25 Chapter 3 Noninvasive fetal blood group genotyping of rhesus D, c, E and 41 of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience Chapter 4 Noninvasive fetal genotyping of human platelet antigen-1a 61 Chapter 5 The controversy about controls for fetal blood group genotyping 69 by cell-free fetal DNA in maternal plasma Chapter 6 A nation-wide fetal RHD screening programme for targeted antenatal 81 and postnatal anti-D immunoglobulin prophylaxis: first-three-month analysis Chapter 7 Summary and concluding remarks 103 Nederlandse samenvatting 111 Dankwoord 117 Curriculum Vitae 123 Chapter 1 General introduction and scope of the thesis Chapter 1 Cell-free fetal nucleic acids in the blood of a pregnant woman are a source of fetal genetic material that can be obtained from the expectant mother by a simple venipuncture.
    [Show full text]
  • Circulating Cell Free Tumor DNA Detection As a Routine Tool Forlung Cancer Patient Management
    Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management Julie Vendrell, Frédéric Tran Mau-Them, Benoît Beganton, Sylvain Godreuil, Peter Coopman, Jérôme Solassol To cite this version: Julie Vendrell, Frédéric Tran Mau-Them, Benoît Beganton, Sylvain Godreuil, Peter Coopman, et al.. Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management. International Journal of Molecular Sciences, MDPI, 2017, 18 (2), pp.264. 10.3390/ijms18020264. hal-01784728 HAL Id: hal-01784728 https://hal.archives-ouvertes.fr/hal-01784728 Submitted on 25 May 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License International Journal of Molecular Sciences Review Circulating Cell Free Tumor DNA Detection as a Routine Tool for Lung Cancer Patient Management Julie A. Vendrell 1, Frédéric Tran Mau-Them 1, Benoît Béganton 2,3,4,5, Sylvain Godreuil 6, Peter Coopman 2,3,4,5 and Jérôme Solassol 1,2,3,5,* 1 CHU Montpellier, Arnaud de Villeneuve
    [Show full text]
  • Cell-Free Fetal DNA in Maternal Blood: New Possibilities in Prenatal Diagnostics1)
    DOI 10.1515/labmed-2012-0078 J Lab Med 2012; aop Molecular-Genetic and Cytogenetic Diagnostics Editor: H.-G. Klein Markus Stumm *, Rolf-Dieter Wegner and Wera Hofmann Cell-free fetal DNA in maternal blood: new 1) possibilities in prenatal diagnostics Abstract: Cell free fetal DNA (cff-DNA) in maternal blood of prenatal diagnostics, it has been necessary so far to has given rise to the possibility of new non-invasive obtain placental or fetal material through chorionic villus approaches in prenatal genetic diagnoses. In contrast to sampling (CVS) in the first trimester of pregnancy or by the established invasive techniques chorionic villi sam- amniocentesis (AC) in the second trimester of pregnancy. pling and amniocentesis, both associated with specific Both methods, however, are invasive and fraught with a risk (0.5 % – 1 % ) for procedure-related abortions, cff-DNA procedure-related miscarriage risk of 0.5 % – 1 % , so that is simply gained by maternal venous blood sampling, they are performed only after a thorough clinical indica- without any risk for the embryo or fetus. Therefore, cff- tion [1] . For the detection of the most common fetal aneu- DNA offers the possibility for riskless genetic diagnoses ploidies (trisomy 13, 18 and 21), non-invasive screening of ongoing pregnancies. Molecular genetic techniques are tests are used additionally that are based on ultrasound already used for the qualitative detection of specific fetal and the determination of hormone and protein para- sequences, such as paternal inherited or spontaneous meters in maternal serum. This is not a diagnostic pro- originated (de novo) mutations. Until recently, the intro- cedure, but merely risk assessments that due to limited duction of digital PCR and next generation sequencing sensitivity and specificity result in a relatively large technologies has shown that a reliable quantitative detec- number of false positive and false negative results (about tion of mutant alleles as well as of clinical relevant aneu- 5 % ).
    [Show full text]
  • The Accuracy of Cell-Free Fetal DNA Based
    The accuracy of cell-free fetal DNA based non- invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis Mackie, Fiona; Hemming, Karla; Allen, Stephanie; Morris, R. Katie; Kilby, Mark; MacKie, Fiona DOI: 10.1111/1471-0528.14050 License: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) Document Version Peer reviewed version Citation for published version (Harvard): Mackie, F, Hemming, K, Allen, S, Morris, RK, Kilby, M & MacKie, F 2016, 'The accuracy of cell-free fetal DNA based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis', BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.14050 Link to publication on Research at Birmingham portal Publisher Rights Statement: Checked for eligibility: 27/04/2016. This is the peer reviewed version of the following article: Mackie FL, Hemming K, Allen S, Morris RK, Kilby MD. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. BJOG 2016; DOI: 10.1111/1471-0528.14050. , which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/1471-0528.14050/full. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving." General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.
    [Show full text]
  • Circulating Tumor DNA As a Liquid Biopsy: Current Clinical Applicati…Ture Directions: Page 2 of 3 | Cancer Network | the Oncology Journal 11/19/17, 10(40 PM
    Circulating Tumor DNA as a Liquid Biopsy: Current Clinical Applicati…ture Directions: Page 2 of 3 | Cancer Network | The Oncology Journal 11/19/17, 10(40 PM Circulating Tumor DNA as a Liquid Biopsy: Current Clinical Applications and Future Directions: Page 2 of 3 By Kimberly M. Komatsubara, MD and Adrian G. Sacher, MD, MMSc Tuesday, August 15, 2017 Issue: Volume: 31 8 Oncology Journal, Cancer and Genetics Abstract / Synopsis: Tumor genomic sequencing has become part of routine oncology practice in many tumor types, in order to identify potentially targetable mutations and to personalize cancer care. Plasma genotyping via circulating tumor DNA analysis is a noninvasive and rapid alternative method of detecting and monitoring genomic alterations throughout the course of disease. Multiple assays have been developed to date, each with different test characteristics and degrees of clinical validation. Here we review the clinical data supporting these different plasma genotyping methodologies, and present a practical approach to the interpretation of the results of these tests. While the clinical application of plasma genotyping has been most extensively validated in the metastatic setting—for the detection of targetable alterations at the time of initial diagnosis or disease progression— this technology holds significant promise across many tumor types and stages of disease. We will also review emerging applications of plasma genotyping that are currently under clinical investigation. http://www.cancernetwork.com/oncology-journal/circulating-tumor-dna-li…id-biopsy-current-clinical-applications-and-future-directions/page/0/1 Page 1 of 4 Circulating Tumor DNA as a Liquid Biopsy: Current Clinical Applicati…ture Directions: Page 2 of 3 | Cancer Network | The Oncology Journal 11/19/17, 10(40 PM Guide to Interpretation of Plasma Genotyping Results Oncology (Williston Park).
    [Show full text]
  • Fetal Sex and RHD Genotyping with Digital PCR Demonstrates Greater Sensitivity Than Real-Time PCR Kelly A
    Clinical Chemistry 61:11 Molecular Diagnostics and Genetics 1399–1407 (2015) Fetal Sex and RHD Genotyping with Digital PCR Demonstrates Greater Sensitivity than Real-time PCR Kelly A. Sillence,1 Llinos A. Roberts,2 Heidi J. Hollands,2 Hannah P. Thompson,1 Michele Kiernan,1 Tracey E. Madgett,1 C. Ross Welch,2 and Neil D. Avent1* BACKGROUND: Noninvasive genotyping of fetal RHD inconclusive results, particularly when samples express (Rh blood group, D antigen) can prevent the unnecessary high levels of background maternal cell-free DNA. administration of prophylactic anti-D to women carry- © 2015 American Association for Clinical Chemistry ing RHD-negative fetuses. We evaluated laboratory methods for such genotyping. Diagnosis of fetal sex, RHD (Rh blood group, D anti- METHODS: Blood samples were collected in EDTA tubes gen)3 genotype, and chromosomal abnormalities can be and Streck® Cell-Free DNA™ blood collection tubes achieved only through analysis of fetal DNA. Initially, (Streck BCTs) from RHD-negative women (n ϭ 46). this could be achieved through invasive procedures such Using Y-specific and RHD-specific targets, we investi- as amniocentesis and chorionic villus sampling, quoted as gated variation in the cell-free fetal DNA (cffDNA) frac- having a 1% risk of miscarriage (1). Since the discovery tion and determined the sensitivity achieved for optimal 4 and suboptimal samples with a novel Droplet Digital™ of cell-free fetal DNA (cffDNA) in maternal plasma, PCR (ddPCR) platform compared with real-time quan- noninvasive prenatal testing is now a clinical reality (1– titative PCR (qPCR). 5). Fetal sex determination is offered in the clinic for families at risk of X-linked disorders, such as Duchenne RESULTS: The cffDNA fraction was significantly larger for muscular dystrophy (6).
    [Show full text]